drugset / Trial / NCT05119413

Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma

NCT05119413

Phase 2 Completed 40 enrolled Centre Hospitalier Universitaire de Nice
RandomizedParallel-groupDouble-blindTreatment

Summary

Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.

Timeline

Start
2021-11-30
Primary completion
2022-09-16
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroquinone Small molecule Topical
Subject isobutylamido-thiazolyl-resorcinol Unknown Topical
Background Isotretinoin Other / unclassified Topical